FDA Advisory Committee Recommends Approval Of InterMune’s Esbriet(R) (pirfenidone) For Idiopathic Pulmonary Fibrosis
InterMune, Inc. (Nasdaq: ITMN) announced that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function...
(more...)
(more...)
